Overview of antifungal agents

Area of Science:

• Clinical Pharmacy
• Infectious Diseases
• Pharmacology

Background:

• Fungal infections pose a significant threat, necessitating effective antifungal therapies.
• Intravenous and inhalational routes are crucial for systemic and pulmonary fungal infections.
• A wide array of antifungal agents are available, each with unique properties.

Purpose of the Study:

• To provide a comprehensive clinical review of currently available intravenous and inhalational antifungals.
• To emphasize pharmacodynamics, pharmacokinetics, drug interactions, and adverse events.
• To review evidence from clinical trials demonstrating the efficacy of these antifungal agents.

Main Methods:

• Literature review of clinical trials and pharmacological data.
• Focus on antifungals administered via intravenous or inhalational routes.
• Analysis of pharmacodynamic and kinetic properties, drug interactions, and adverse events.

Main Results:

• Detailed review of amphotericin B (including lipid formulations), fluconazole, itraconazole, posaconazole, voriconazole, caspofungin, micafungin, anidulafungin, and flucytosine.
• Emphasis on clinical efficacy, safety profiles, and pharmacokinetic/pharmacodynamic considerations.
• Summarized evidence from selected clinical trials supporting the use of these antifungals.

Conclusions:

• Clinicians require a thorough understanding of available antifungals for optimal patient management.
• Individualized selection based on drug properties, interactions, and patient factors is essential.
• Continued review of clinical evidence ensures effective treatment strategies for fungal infections.